தலை ஆஃப் உலகளாவிய வளர்ச்சி News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from தலை ஆஃப் உலகளாவிய வளர்ச்சி. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In தலை ஆஃப் உலகளாவிய வளர்ச்சி Today - Breaking & Trending Today

Zai Lab Limited (ZLAB) Reports First Patient Treated in China in Registrational Phase 2 TRIDENT-1 Study of Repotrectinib

Zai Lab Limited (ZLAB) Reports First Patient Treated in China in Registrational Phase 2 TRIDENT-1 Study of Repotrectinib
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Hong Kong , Alan Sandler , Point Therapeutics Inc , Oncology Of Zai Lab , Zai Lab , World Health Organization , Drug Administration , Head Of Global Development , Zai Lab Limited , Lab Limited , Turning Point Therapeutics , Turning Point , Greater China , Global Development , Blinded Independent Central Review , Non Small Cell Lung Cancer , ஹாங் காங் , ஆலன் சாண்ட்லர் , பாயஂட் சிகிச்சை இன்க் , ஜா ஆய்வகம் , உலகம் ஆரோக்கியம் ஆர்கநைஸேஶந் , தலை ஆஃப் உலகளாவிய வளர்ச்சி , ஜா ஆய்வகம் வரையறுக்கப்பட்டவை , ஆய்வகம் வரையறுக்கப்பட்டவை , திருப்புதல் பாயஂட் சிகிச்சை , திருப்புதல் பாயஂட் ,

Zai Lab Announces First Patient Treated in China in the

Zai Lab Announces First Patient Treated in China in the Registrational Phase 2 TRIDENT-1 Study of Repotrectinib
May 28, 2021 07:30 ET
| Source:
Zai Lab Limited
Zai Lab Limited
TRIDENT-1 study is enrolling patients with ROS1+ advanced NSCLC and NTRK+ advanced solid tumors.
SHANGHAI and SAN FRANCISCO, May 28, 2021 (GLOBE NEWSWIRE) Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company today announced dosing of the first patient in China in the registrational Phase 2 portion of TRIDENT-1 study of repotrectinib being conducted by its partner Turning Point Therapeutics, Inc. and Zai Lab in patients with ROS1+ advanced non-small cell lung cancer (NSCLC) and NTRK+ advanced solid tumors. Zai Lab has an exclusive license agreement with Turning Point for the development and commercialization of repotrectinib in Greater China (mainland China, Hong Kong, Macau, and Taiwan). ....

Hong Kong , Alan Sandler , Point Therapeutics Inc , Oncology Of Zai Lab , Zai Lab , World Health Organization , Drug Administration , Head Of Global Development , Zai Lab Limited , Lab Limited , Turning Point Therapeutics , Turning Point , Greater China , Global Development , Blinded Independent Central Review , Non Small Cell Lung Cancer , Nasdaq Zlab , Zai Lab Limited , ஹாங் காங் , ஆலன் சாண்ட்லர் , பாயஂட் சிகிச்சை இன்க் , ஜா ஆய்வகம் , உலகம் ஆரோக்கியம் ஆர்கநைஸேஶந் , தலை ஆஃப் உலகளாவிய வளர்ச்சி , ஜா ஆய்வகம் வரையறுக்கப்பட்டவை , ஆய்வகம் வரையறுக்கப்பட்டவை ,

Job vacancies: eLearning Content Developer and Kids' Athletics Manager | NEWS

World Athletics logo
World Athletics is looking for an eLearning Content Developer and a Kids Athletics Manager to join its development department.
Reporting to the Head of Global Development, the eLearning Content Developer s primary responsibilites will be to oversee the eLearning content strategy, develop training modules and courses for online learning, produce curricula and storyboards, select the right learning tools in cooperation with our eLearning service provider and ensure quality control of the finished eLearning packages.
Also reporting to the Head of Global Development, the Kids Athletics Manager will be responsible for assisting with the creation and development and overseeing delivery and promotion of the new World Athletics kids athletics programme at a worldwide level. ....

Head Of Global Development , World Athletics , Learning Content Developer , Kid Athletics Manager , Global Development , Athletics Manager , தலை ஆஃப் உலகளாவிய வளர்ச்சி , உலகம் தடகள , உலகளாவிய வளர்ச்சி , தடகள மேலாளர் ,

Zai Lab Announces Financial Results for Second-half and Full-year 2020

Zai Lab Announces Financial Results for Second-half and Full-year 2020
March 01, 2021 07:00 ET
| Source:
Zai Lab Limited
Zai Lab Limited
Company to Host Conference Call and Webcast Today at 8:00 a.m. ET
SHANGHAI and SAN FRANCISCO, March 01, 2021 (GLOBE NEWSWIRE) Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today reported financial results for the second half and full year of 2020, along with corporate updates.
“2020 was another year of great accomplishment for Zai Lab,” said Dr. Samantha Du, Founder, Chairperson and Chief Executive Officer of Zai Lab. “We successfully launched ZEJULA for both second-line and first-line ovarian cancer and Optune for glioblastoma in China. We submitted NDAs and were granted priority reviews by China’s National Medical Products Administration (NMPA) for both QINLOCK for advanced gastrointestinal stromal tumors (GIST) and NUZY ....

United States , United Kingdom , Hong Kong , Dburns Mcclellan , Mike Zanoni , Alan Sandler , Optune Lua , Billy Cho , Ryo Imai Robert Flamm , Zai Lab , Zai Lab Limited , China National Medical Products Administration , European Union , Zai Lab Forward , Society For Immunotherapy Of Cancer , Drug Administration , Zai Lab Annual Report On Form , Company To Host Conference Call , China National Healthcare Security Administration , Exchange Commission , Hong Kong Department Of Health , National Reimbursement Drug List , Head Of Global Development , Business Development , Host Conference Call , Webcast Today ,